Analysts Set LivaNova PLC (NASDAQ:LIVN) Price Target at $69.17

Shares of LivaNova PLC (NASDAQ:LIVN) have earned an average recommendation of “Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $69.17.

LIVN has been the topic of several research reports. The Goldman Sachs Group initiated coverage on LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price on the stock. StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 16th. Robert W. Baird raised their price objective on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Mizuho cut their price objective on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research report on Monday, November 25th.

LivaNova Trading Down 1.3 %

Shares of LIVN opened at $50.50 on Tuesday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.74 billion, a P/E ratio of 120.24 and a beta of 0.98. The stock’s fifty day simple moving average is $52.25 and its 200 day simple moving average is $51.94. LivaNova has a twelve month low of $43.15 and a twelve month high of $64.47.

Hedge Funds Weigh In On LivaNova

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Fifth Third Bancorp lifted its position in LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after purchasing an additional 332 shares during the period. Hexagon Capital Partners LLC lifted its position in LivaNova by 117.8% in the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after purchasing an additional 370 shares during the period. Lazard Asset Management LLC acquired a new stake in LivaNova in the first quarter worth approximately $84,000. Canada Pension Plan Investment Board acquired a new stake in LivaNova in the second quarter worth approximately $88,000. Finally, Central Pacific Bank Trust Division acquired a new stake in LivaNova in the third quarter worth approximately $178,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.